RELMADA THERAPEUTICS, INC.

A clinical-stage biotech developing novel therapies for CNS diseases and oncology.

RLMD | NDAQ

Overview

Corporate Details

ISIN(s):: US75954H1005 (+1 more)
LEI:
Country:: United States of America
Address:: 2222 PONCE DE LEON BLVD. 3RD FLOOR, 33134 CORAL GABLES
Website:: https://www.relmada.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative and novel treatments for debilitating disorders. The company's primary research area is central nervous system (CNS) diseases, with a significant focus on therapies for major depressive disorder (MDD), including its lead candidate esmethadone. Relmada is also advancing its development pipeline into oncology, with programs such as NDV-01 for urologic cancers. The company's mission is to create transformative medicines that improve human health.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
	2025-11-04 13:00	Regulatory News Service 8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)	English	34.7 MB

Automate Your Workflow. Get a real-time feed of all RELMADA THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RELMADA THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for RELMADA THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Nexxen International Ltd. End-to-end programmatic ad platform for advertisers, agencies, & publishers, specializing in video & CTV.	United States of America	NEXN
NFL Biosciences Develops botanical drug candidates to treat smoking and alcohol addictions.	France	ALNFL
NGS Group Nordic staffing & recruitment for healthcare, education, and social services sectors.	Sweden	NGS
Nihon M&A Center Holdings Inc. M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.	Japan	2127
Noile-Immune Biotech Inc. Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.	Japan	4893
NRGene Technologies Ltd. AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.	Israel	NRGN
Nuvectis Pharma, Inc. Clinical-stage biopharma developing precision medicines for serious oncological conditions.	United States of America	NVCT
Nykode Therapeutics ASA Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.	Norway	NYKD
Ocugen, Inc. Develops gene/cell therapies and vaccines, specializing in blindness and public health.	United States of America	OCGN
Oculis Holding AG Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.	Switzerland	OCS